Cambridge's AVROBIO Lands $60M to Push Fabry, Rest of Pipeline Into the Clinic By Sam | January 31, 2018 The company plans to initiate a Phase 2 clinical trial this year with AVR-RD-01 in Fabry disease. Source: BioSpace Posted in BioPharma